Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The overall aim of this study is to prospectively validate the superiority of the Immunoscore
as a decision guidance for adjuvant chemotherapy in stage III colon cancer patients, in
comparison to the conventional TNM-based high- or low-risk classification.